Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
FDA approved lisocabtagene maraleucel, the first CAR-T for relapsed / refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.
In this WebMD article, Dr. Koffman provides practical advice on how patients can receive assistance paying for this expensive and potentially lifesaving therapy.
Join CLL / SLL expert Dr. Susan O’Brien, and 20-year CLL survivor Terry Evans, as they explain the CLL / SLL treatment landscape, what is known and unknown, and describe how to better participate in shared decision-making with your healthcare provider by increasing your knowledge and having a plan in place for your future treatment moves.
Dr. Mazyar Shadman and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).
Playing CLL / SLL Chess: Planning Your Therapy Moves Wednesday, October 26, 2022 12 PM PT / 1 PM MT / 2 PM CT / 3 PM ET (Duration 90 minutes) Register Now!
Cellular therapies are a special type of immunotherapy that use cells, a “living drug”, to treat CLL / SLL. CAR-T is a revolutionary therapy in CLL and other blood cancers, which is currently available through clinical trials. Learn more about this “living drug” and other cellular therapy options for CLL patients with Dr. Mazyar Shadman.
Chemotherapy Chemotherapy damages the cells’ DNA and non-specifically kills anything that grows quickly, such as cancer cells, but also skin, hair, gut, and normal blood cells. In CLL / SLL, common
Immunotherapy Immunotherapy works by harnessing the body’s own immune system and offers options for powerful, yet well-tolerated, therapies. Examples include monoclonal antibodies (rituximab, obinutuzumab, and others) that recognize the cancer, drugs
One click to our most popular content.
